China Universal Asset Management Co., Ltd. Mirati Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 May 21, 2024	BUY	$41.99 - $62.38 $340,832 - $506,338	8,117 New	8,117 $476,000
Q4 2023 Jan 23, 2024	BUY	$41.99 - $62.38 $267,266 - $397,048	6,365 Added 363.3%	8,117 $477,000
Q3 2023 May 21, 2024	BUY	$27.8 - $45.35 $27,522 - $44,896	990 Added 129.92%	1,752 $76,000
Q3 2023 Oct 30, 2023	BUY	$27.8 - $45.35 $27,522 - $44,896	990 Added 129.92%	1,752 $76,000
Q2 2023 May 21, 2024	SELL	$36.13 - $49.49 $867 - $1,187	-24 Reduced 3.05%	762 $27,000
Q2 2023 Jul 27, 2023	SELL	$36.13 - $49.49 $867 - $1,187	-24 Reduced 3.05%	762 $28,000
Q1 2023 May 21, 2024	BUY	$36.54 - $54.26 $7,344 - $10,906	201 Added 34.36%	786 $29,000
Q1 2023 Apr 27, 2023	BUY	$36.54 - $54.26 $7,344 - $10,906	201 Added 34.36%	786 $29,000
Q4 2022 May 21, 2024	BUY	$41.27 - $98.62 $24,142 - $57,692	585 New	585 $26,000
Q4 2022 Jan 31, 2023	BUY	$41.27 - $98.62 $2,641 - $6,311	64 Added 12.28%	585 $27,000
Q3 2022 Oct 21, 2022	BUY	$59.5 - $86.7 $30,999 - $45,170	521 New	521 $36,000
Q2 2022 Aug 12, 2022	SELL	$39.16 - $88.71 $9,672 - $21,911	-247 Closed	0 $0
Q1 2022 Apr 25, 2022	SELL	$75.82 - $150.97 $1.2 Million - $2.39 Million	-15,853 Reduced 98.47%	247 $20,000
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $2.13 Million - $3.06 Million	16,100 New	16,100 $2.36 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account